Sihuan Pharmaceutical Buys 5.00 Million Shares for Award Scheme After 37.7% Revenue Surge

Bulletin Express06-08

On 8 June 2026, Sihuan Pharmaceutical executed an on-market purchase of 5.00 million shares at an average price of HK$0.9064 per share under its 2022 Share Award Scheme. The transaction represents approximately 0.0548% of the company’s issued share capital, excluding treasury shares.

The board stated that the buyback supports long-term talent retention and aligns management incentives with shareholder interests, following a year of marked financial improvement.

Key 2025 financial highlights: • Revenue reached RMB2.62 billion, up 37.7% year on year. • Net profit turned positive at RMB185.40 million, reversing the prior loss. • Medical aesthetics revenue nearly doubled to RMB1.49 billion, contributing 57% of group revenue and surpassing the 50% threshold for the first time. • The innovative drug segment more than doubled revenue, entering a full commercialization phase with ongoing gains in product launches and NRDL inclusion.

Management underscored that the share purchase coincides with an “accelerated phase of profitable growth” and will reinforce execution of the group’s dual-engine strategy in medical aesthetics and biopharmaceuticals. The company continues to expand globally, highlighted by its investment in Swiss firm Suisselle to access the European medical aesthetics market.

Founded in 2010 and listed on the Hong Kong Main Board, Sihuan Pharmaceutical focuses on innovation-driven medical aesthetics and biopharmaceuticals, supported by internal R&D, broad product pipelines, and an established sales network.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154080359?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154080359","market":"us","top_or_hot":-1,"title":"Sihuan Pharmaceutical Buys 5.00 Million Shares for Award Scheme After 37.7% Revenue Surge","media":"Bulletin Express","content":"<p>On 8 June 2026, Sihuan Pharmaceutical executed an on-market purchase of 5.00 million shares at an average price of HK$0.9064 per share under its 2022 Share Award Scheme. The transaction represents approximately 0.0548% of the company’s issued share capital, excluding treasury shares.</p>\n<p>The board stated that the buyback supports long-term talent retention and aligns management incentives with shareholder interests, following a year of marked financial improvement.</p>\n<p>Key 2025 financial highlights:\n• Revenue reached RMB2.62 billion, up 37.7% year on year.  \n• Net profit turned positive at RMB185.40 million, reversing the prior loss.  \n• Medical aesthetics revenue nearly doubled to RMB1.49 billion, contributing 57% of group revenue and surpassing the 50% threshold for the first time.  \n• The innovative drug segment more than doubled revenue, entering a full commercialization phase with ongoing gains in product launches and NRDL inclusion.</p>\n<p>Management underscored that the share purchase coincides with an “accelerated phase of profitable growth” and will reinforce execution of the group’s dual-engine strategy in medical aesthetics and biopharmaceuticals. The company continues to expand globally, highlighted by its investment in Swiss firm Suisselle to access the European medical aesthetics market.</p>\n<p>Founded in 2010 and listed on the Hong Kong Main Board, Sihuan Pharmaceutical focuses on innovation-driven medical aesthetics and biopharmaceuticals, supported by internal R&D, broad product pipelines, and an established sales network.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharmaceutical Buys 5.00 Million Shares for Award Scheme After 37.7% Revenue Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharmaceutical Buys 5.00 Million Shares for Award Scheme After 37.7% Revenue Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-08 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 8 June 2026, Sihuan Pharmaceutical executed an on-market purchase of 5.00 million shares at an average price of HK$0.9064 per share under its 2022 Share Award Scheme. The transaction represents approximately 0.0548% of the company’s issued share capital, excluding treasury shares.</p>\n<p>The board stated that the buyback supports long-term talent retention and aligns management incentives with shareholder interests, following a year of marked financial improvement.</p>\n<p>Key 2025 financial highlights:\n• Revenue reached RMB2.62 billion, up 37.7% year on year.  \n• Net profit turned positive at RMB185.40 million, reversing the prior loss.  \n• Medical aesthetics revenue nearly doubled to RMB1.49 billion, contributing 57% of group revenue and surpassing the 50% threshold for the first time.  \n• The innovative drug segment more than doubled revenue, entering a full commercialization phase with ongoing gains in product launches and NRDL inclusion.</p>\n<p>Management underscored that the share purchase coincides with an “accelerated phase of profitable growth” and will reinforce execution of the group’s dual-engine strategy in medical aesthetics and biopharmaceuticals. The company continues to expand globally, highlighted by its investment in Swiss firm Suisselle to access the European medical aesthetics market.</p>\n<p>Founded in 2010 and listed on the Hong Kong Main Board, Sihuan Pharmaceutical focuses on innovation-driven medical aesthetics and biopharmaceuticals, supported by internal R&D, broad product pipelines, and an established sales network.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"","article_id":"1154080359","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154080359","pubTimestamp":1780918976,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 8 June 2026, Sihuan Pharmaceutical executed an on-market purchase of 5.00 million shares at an average price of HK$0.9064 per share under its 2022 Share Award Scheme. The transaction represents...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00460":"四环医药"},"translate_title":"收入激增37.7%四环医药购买500万股奖励计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"On 8 June 2026, Sihuan Pharmaceutical executed an on-market purchase of 5.00 million shares at an average price of HK$0.9064 per share under its 2022 Share Award Scheme. The transaction represents approximately 0.0548% of the company’s issued share capital, excluding treasury shares.\nThe board stated that the buyback supports long-term talent retention and aligns management incentives with shareholder interests, following a year of marked financial improvement.\nKey 2025 financial highlights:\n• Revenue reached RMB2.62 billion, up 37.7% year on year.  \n• Net profit turned positive at RMB185.40 million, reversing the prior loss.  \n• Medical aesthetics revenue nearly doubled to RMB1.49 billion, contributing 57% of group revenue and surpassing the 50% threshold for the first time.  \n• The innovative drug segment more than doubled revenue, entering a full commercialization phase with ongoing gains in product launches and NRDL inclusion.\nManagement underscored that the share purchase coincides with an “accelerated phase of profitable growth” and will reinforce execution of the group’s dual-engine strategy in medical aesthetics and biopharmaceuticals. The company continues to expand globally, highlighted by its investment in Swiss firm Suisselle to access the European medical aesthetics market.\nFounded in 2010 and listed on the Hong Kong Main Board, Sihuan Pharmaceutical focuses on innovation-driven medical aesthetics and biopharmaceuticals, supported by internal R&D, broad product pipelines, and an established sales network.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154080359","isCrawlerRequest":true}